NCT02084251已完成1 期
Safety, Tolerability and Pharmacokinetics of Single Dose of PB-119 in Healthy Volunteers
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 70
- 试验地点
- 1
- 主要终点
- Safety/Adverse Event Outcome Measure
研究概览
简要总结
GLP-1 analogues have been widely used because of their unique advantages (no risk of hypoglycemia) due to their glucose dependent mechanism. Due to the short half-life of peptide in plasma, peptides have to be administered frequently (i.e. BID for Byetta, with Exenatide as API).To improve the patients compliance and reduce potential adverse events associated with GLP-1 analogues, a long acting GLP-1 analogue (PB-119), which may be administered once weekly, was developed by PegBio Inc. In order to provide rational for dosage range to be studied in Phase Ib, the safety profile, tolerance, and pharmacokinetic behavior of PB-119 in healthy subjects will be studied in this randomized, controlled dose escalating trial.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Male or female volunteers, ages: between 18-45;
- •Body weight： female >= 45kg, male >=50kg, BMI >=19-24kg/m2
- •Physical examination, blood routine, urine routine, liver and kidney function and related laboratory tests are normal or slightly abnormal but not clinically significant;
- •Read, agree, and sign the informed consent;
- •Be able to communicate with the investigator and finish the study according to the protocol.
- •Exclusion Criteria （anyone or more of the following):
- •Allergic to the API or excipients used (citric acid, mannitol, Meta-Cresol);
- •Experiencing clinically significant disease or surgery within 4 weeks before the study;
- •Clinically significant disease history in systems including cardiovascular system, endocrine system, neutral system, immunology system, psychiatry，metabolic disorder;
- •Disease history of gastrointestinal tract, liver, and kidney (for example, the Partial resection surgery in GI tract, liver, or kidney);
- •Fever history within 3 days of the screening;
- •Clinical significant abnormality found in laboratory tests (blood, urine routine test) within 2 weeks before study;
- •ECG or vital signs is clinically significant abnormality as judged by the Investigator( systolic blood pressure <90mmHg or ≥140mmHg; diastolic blood pressure<60mmHg or ≥90mmHg; heart rate <50bpm or >100bpm);
- •Antibody test for HIV, BsAg, C hepatitis, or Microspironema pallidum positive;
- •Alcoholics or drink frequently within 6 months of trial (more than 14 unit of alcohol, in which 1 unit is 360mL beers, or 45 ml wine with 40% alcohol content, or 150mL port wine;
- •Addicted to cigarette, tea, coffee or drugs;
- •Have specific requirement for diets (or allergic to any food);
- •Have been administered in the past 2 weeks with any drug (such as antibiotics, anticoagulant, diuretics) that might interfere the PK profile of drug/drug candidate to be used in this study;
- •Participated in any clinical trial in the past 3 months;
- •Donated blood of more than 360 ml in the past 3 months;
- •Plan to be pregnant herself or his spouse in the next 6 months;
- •Females administered with any oral contraceptive 30 days before the study or during the study;
- •Females dosed with long acting estrogen or progestin (injections or implant) 6 months before the study or during the study;
- •Females at childbearing age that had unprotected intercourse 14 days before the study or will have during the study;
- •Female who is pregnant or nursing;
- •Anybody who might not be able to complete the study, or considered not appropriate by the investigator.
排除标准
- 未提供
研究组 & 干预措施
Exenatide analogue, Injection
Experimental
PB-119 will be administered once weekly subcutaneously at dosage of 2μg、5μg、10μg、25μg、50μg、100μg、200μg or 400μg.
干预措施: PB-119 (Drug)
结局指标
主要结局
Safety/Adverse Event Outcome Measure
时间窗: Up to 3 weeks
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Efficacy and Safety of GLP-1 first therapy compared with Insulin GLP-1 relay therapy in type 2 diabetes with inadequate glucose control: a randomized, open-label, multicenter parallel-group studyType 2 diabetesJPRN-UMIN000014140Kanazawa university Department of Disease Control and Homeostasis120
进行中（未招募）
1 期
se of GLP-1 analogs in the treatment of multiple sclerosisEUCTR2019-003001-94-SKekárska fakulta UK Bratislava50
已完成
不适用
ong-term efficacy and safety of the GLP-1 receptor agonist liraglutide in Japanese patients with type 2 diabetes mellitus.Type 2 Diabetes mellitusJPRN-UMIN000037603akakinen clinic1,000
已完成
1 期
Effects of Oral GLP-1 on Glucose Homeostasis and Appetite Profile in Healthy Male SubjectsGlucose HomeostasisNCT00822003University Hospital, Basel, Switzerland16
已完成
不适用
GLP-1 analogue therapy on glycemic control in patients undergoing cardiac surgerytype2 diabetesJPRN-UMIN000008003GLOLIA investigation group70